Metabolic Mechanism of Qizhi Capsule for Treating Hyperlipoidemia Based on Chinmedomics Strategy
Biomedical Chromatography · 2025
DOI: 10.1002/bmc.70192 ↗Kurz gefasst
Fachartikel in der Zeitschrift Biomedical Chromatography, 2025. Verfasst von Heng Fang und 9 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Integration and Innovation of Classic Formula and Modern Chinese medicine, National Chinmedomics Research Center, National TC…. Hauptthemen laut MEDLINE: Drugs, Chinese Herbal, Hyperlipidemias, Metabolomics, Hypolipidemic Agents. Die Arbeit nennt 33 Literaturangaben. Gefördert von: National Natural Science Foundation of China, QiZhi, University Nursing Program for Young Scholars with Creative Talents in Heilongjiang Province.
Abstract (Originalsprache)
To elucidate the active ingredients, and mechanism of action of Qizhi Capsules (QZC), a traditional Chinese patent medicine for the treatment of hyperlipidemia (HP). A high‐fat diet‐induced HP rat model was used to evaluate the therapeutic effect of QZC. Then, we integrated metabolomics, serum pharmacochemistry, network pharmacology, and molecular docking strategies for investigation. Results showed that QZC significantly alleviated the physiological symptoms of HP, with remarkable restoration of the levels of cholesterol, triglycerides, low‐density lipoprotein, and high‐density lipoprotein. It can also reverse pathological changes in liver function to healthy levels. Besides, metabolomic analysis identified 24 metabolites as biomarkers which are highly related to HP. All the markers were settled back to normal with the intervention of QZC. Seventy‐seven compounds originated from QZC were found in blood; 17 of them were highly related to the trajectory change of biomarkers of HP. These compounds were the potential effective constituents related to its clinical efficacy, such as Emodin et al. These ingredients regulated the biomarker farnesol to target Farnesoid X receptor (FXR) involved in cholesterol and triglyceride metabolism with HP. QZC possesses a favorable efficacy on HP; the core mechanism may activate FXR by modulating farnesol with multiple components, thereby reversing the metabolism of HP.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- State Key Laboratory of Integration and Innovation of Classic Formula and Modern Chinese medicine, National Chinmedomics Research Center, National TCM Key Laboratory of Serum Pharmacochemistry, Metabolomics Laboratory,…
- State Key Laboratory of Dampness Syndrome, The Second Affiliated Hospital Guangzhou University of Chinese Medicine, Guangzhou, China.
- State Key Laboratory of Quality Research in Chinese Medicine, Macau University of Science and Technology, AvenidaWai Long, Taipa, Macau.
Förderung
- National Natural Science Foundation of China
- QiZhi
- University Nursing Program for Young Scholars with Creative Talents in Heilongjiang Province
- Heilongjiang Touyan Innovation Team Program
Zitieren
APA
Fang, H., Yan, G., Yang, L., Kong, L., Sun, Y., Sun, H., Bai, B., YingHan, Song, H., & Wang, X. (2025). Metabolic Mechanism of Qizhi Capsule for Treating Hyperlipoidemia Based on Chinmedomics Strategy. Biomedical Chromatography. https://doi.org/10.1002/bmc.70192
Vancouver
Fang H, Yan G, Yang L, Kong L, Sun Y, Sun H, et al. Metabolic Mechanism of Qizhi Capsule for Treating Hyperlipoidemia Based on Chinmedomics Strategy. Biomedical Chromatography. 2025. doi:10.1002/bmc.70192
BibTeX
@article{Fang2025,
author = {Fang, Heng and Yan, Guangli and Yang, Le and Kong, Ling and Sun, Ye and Sun, Hui and Bai, Biwei and YingHan and Song, Hongwei and Wang, Xijun},
title = {Metabolic Mechanism of Qizhi Capsule for Treating Hyperlipoidemia Based on Chinmedomics Strategy},
journal = {Biomedical Chromatography},
year = {2025},
doi = {10.1002/bmc.70192}
}
EUVIMED